Work

Prophylactic vedolizumab to facilitate use of immune-checkpoint inhibitors in cancer patients at high risk of immune-mediated colitis.

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.12134

Authors: Hemant Khandelia, David Hockenbery, Daniel S. Hippe, Evan Thomas Hall, Sylvia Lee, Lisa May Ling Tachiki, Joshua Veatch, Natalie J. Miller, Andrea M. Perdue, Julia K. Majovski, Chloe Thorup, Zach Herrin, Kristin A. Province, Shailender Bhatia

Institutions: University of Washington, Fred Hutch Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7162487078

Cites:

Cited by:

Related to: